TIGIT and neoplasm: ICB resistance is driven by multiple factors, including T cell exclusion and dysfunction within the TME, defects in antigen processing, a lack of tumor-associated antigens, and the presence of alternative inhibitory immune checkpoints such as VISTA, TIM-3, LAG-3, and TIGIT.